Karydas Daphne bought MLYS
September 15, 2026 · Form 4 insider transaction
Karydas Daphne bought 3,000 shares of Mineralys Therapeutics, Inc. at $12.02 per share, a transaction worth $36.1K. The trade was recorded as option exercise under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
3,000
Price
$12.02
Total value
$36.1K
InsiderKarydas Daphne
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateSeptember 15, 2026
Filing dateSeptember 17, 2026
Shares owned after9,200
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.